ASCIA Submissions 2024

ASCIA advocates on behalf of ASCIA members to government and other organisations by lodging submissions which are listed below.

• ASCIA has submitted an application to the Medical Services Advisory Committee (MSAC) for a Medical Benefits Schedule (MBS) item number for supervised oral food challenges as part of the National Allergy Council projects that are assigned to ASCIA. Lodged 23 July 2024. Information is available at www.allergy.org.au/about-ascia/info-updates/ascia-application-for-mbs-item-for-supervised-oral-food-challenges

• ASCIA lodged four confidential submissions regarding PBS listing of Dupixent^® (dupilumab) for treatment of severe atopic dermatitis for consideration at the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting under "Other Matters (Change to existing listing)". The PBAC outcomes for the July 2024 meeting are on the PBS website: pbac-web-outcomes-07-2024.pdf (pbs.gov.au) and the entry for dupilumab is on page 28. Submissions to the PBAC, Sanofi, the Health Minister and the Assistant Health Minister were lodged on 9 July 2024.
  ASCIA letter PBAC DUPIXENT 2024-07-09110.13 KB

• ASCIA submission in response to the Department of Health and Aged Care public consultation on a new National Immunisation Strategy for 2025-2030. Lodged 17 June 2024.
  ASCIA letter Immunisation 2024-06-17130.38 KB

• ASCIA letter of support for application on the agenda of the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting: Arexvy^® Respiratory Syncytial Virus (RSV) Vaccine application for new NIP listing - Lodged 29 May 2024. 
  ASCIA letter PBAC AREXVY 2024-05-2952.02 KB

• ASCIA submission to Public Consultation on the refresh of the National Strategic Framework for Chronic Conditions. Lodged 28 April 2024.
  ASCIA Submission Framework 2024-04-2846.21 KB

• ASCIA has lodged five submissions on 24 January 2024 in support of applications for new or updated Pharmaceutical Benefits Scheme (PBS) listings of products (listed below) that are relevant to allergy and immunology. These applications were on the agenda of the March 2024 Pharmaceutical Benefits Advisory Committee (PBAC) meeting as stated on https://www.allergy.org.au/about-ascia/info-updates/pbac-meeting-march-2024.  Outcomes from this meeting are available at https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/pbac-outcomes/2024-03/pbac-web-outcomes-03-2024.pdf

  ASCIA letter PBAC Asthma Dupilumab 2024-01-2467.47 KB - Listing recommended
  ASCIA letter PBAC Asthma Mepolizumab 2024-01-2469.70 KB - Change to clinical criteria recommended
  ASCIA letter PBAC Avacopan 2024-01-2463.78 KB - Listing recommended
  ASCIA letter PBAC Neocate Syneo 2024-01-24115.84 KB - Continued listing recommended
  ASCIA letter PBAC SLE Anifrolumab 2024-01-2463.50 KB - Listing recommended

2024